NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.

NEW YORK – The US Department of Justice announced this week the resolution of two separate laboratory fraud cases, one in which a North Carolina lab allegedly billed Medicaid for unnecessary urine ...

NEW YORK – French startup AlterDiag announced on Wednesday that it has partnered with the Institut Pasteur to develop rapid diagnostic tests for infectious diseases. Researchers from the Institut ...

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.